While newer therapies have transformed chronic ITP management, corticosteroids and intravenous immunoglobulin (IVIG) remain essential for acute treatment. They are often the first-line approach for newly diagnosed ITP and for patients requiring rapid platelet increases. Understanding their role is essential to understanding the ITP therapeutics market.

Corticosteroids — such as prednisone — reduce immune-mediated platelet destruction and are widely used as initial therapy. IVIG provides rapid but temporary platelet increases, useful before surgery or in severe bleeding. According to idiopathic thrombocytopenic purpura itp therapeutics market research, corticosteroids remain the largest drug segment, reflecting their role as first-line therapy and their low cost. IVIG is significant for acute care and special situations.

Innovation includes modified-release steroids with fewer side effects and more convenient IVIG formulations.

Challenges include side effects from prolonged steroid use, IVIG supply constraints, and the need for better long-term options.

Yet the fundamentals are strong: acute ITP care depends on these therapies.

The ITP therapeutics market is expected to continue relying on corticosteroids and IVIG, even as newer agents expand the treatment landscape.

People Also Ask

Q: Why are corticosteroids used first-line in ITP?
A: They reduce immune-mediated platelet destruction and are effective, widely available, and low-cost.

Q: When is IVIG used in ITP?
A: IVIG is used when rapid platelet increases are needed, such as before surgery or during severe bleeding.

Tags: #Corticosteroids #IVIG #ITPTreatment #AcuteCare #Hematology #MarketDrivers